The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results

C. Ripamonti, C. Panzeri, L. Groff, G. Galeazzi, R. Boffi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Malignant bowel obstruction is a common complication in patients with advanced abdominal or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel obstruction, many advanced and terminal cancer patients are considered unfit for surgery. In such patients with a short life expectancy, gastrointestinal symptoms such as nausea, vomiting, continuous and/or colicky pain, can be controlled by using a pharmacologic approach made up of analgesics, antiemetics and antisecretory drugs, without the use of a venting nasogastric tube. Among the antisecretory drugs, octreotide has been shown to reduce nausea and vomiting in bowel-obstructed patients owing to a reduction of gastrointestinal secretions, thus allowing in most patients removal of the nasogastric tube and the associated distress. Preclinical and clinical studies that demonstrated the role of somatostatin and octreotide in bowel obstruction are reviewed.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalTumori
Volume87
Issue number1
Publication statusPublished - 2001

Fingerprint

Octreotide
Somatostatin
Nausea
Vomiting
Pelvic Neoplasms
Antiemetics
Life Expectancy
Abdominal Pain
Analgesics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Bowel obstruction
  • Clinical
  • Experimental
  • Octreotide
  • Somatostatin

ASJC Scopus subject areas

  • Cancer Research

Cite this

The role of somatostatin and octreotide in bowel obstruction : Pre-clinical and clinical results. / Ripamonti, C.; Panzeri, C.; Groff, L.; Galeazzi, G.; Boffi, R.

In: Tumori, Vol. 87, No. 1, 2001, p. 1-9.

Research output: Contribution to journalArticle

@article{03270d80dd7445b9819f16c435b10b00,
title = "The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results",
abstract = "Malignant bowel obstruction is a common complication in patients with advanced abdominal or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel obstruction, many advanced and terminal cancer patients are considered unfit for surgery. In such patients with a short life expectancy, gastrointestinal symptoms such as nausea, vomiting, continuous and/or colicky pain, can be controlled by using a pharmacologic approach made up of analgesics, antiemetics and antisecretory drugs, without the use of a venting nasogastric tube. Among the antisecretory drugs, octreotide has been shown to reduce nausea and vomiting in bowel-obstructed patients owing to a reduction of gastrointestinal secretions, thus allowing in most patients removal of the nasogastric tube and the associated distress. Preclinical and clinical studies that demonstrated the role of somatostatin and octreotide in bowel obstruction are reviewed.",
keywords = "Bowel obstruction, Clinical, Experimental, Octreotide, Somatostatin",
author = "C. Ripamonti and C. Panzeri and L. Groff and G. Galeazzi and R. Boffi",
year = "2001",
language = "English",
volume = "87",
pages = "1--9",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - The role of somatostatin and octreotide in bowel obstruction

T2 - Pre-clinical and clinical results

AU - Ripamonti, C.

AU - Panzeri, C.

AU - Groff, L.

AU - Galeazzi, G.

AU - Boffi, R.

PY - 2001

Y1 - 2001

N2 - Malignant bowel obstruction is a common complication in patients with advanced abdominal or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel obstruction, many advanced and terminal cancer patients are considered unfit for surgery. In such patients with a short life expectancy, gastrointestinal symptoms such as nausea, vomiting, continuous and/or colicky pain, can be controlled by using a pharmacologic approach made up of analgesics, antiemetics and antisecretory drugs, without the use of a venting nasogastric tube. Among the antisecretory drugs, octreotide has been shown to reduce nausea and vomiting in bowel-obstructed patients owing to a reduction of gastrointestinal secretions, thus allowing in most patients removal of the nasogastric tube and the associated distress. Preclinical and clinical studies that demonstrated the role of somatostatin and octreotide in bowel obstruction are reviewed.

AB - Malignant bowel obstruction is a common complication in patients with advanced abdominal or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel obstruction, many advanced and terminal cancer patients are considered unfit for surgery. In such patients with a short life expectancy, gastrointestinal symptoms such as nausea, vomiting, continuous and/or colicky pain, can be controlled by using a pharmacologic approach made up of analgesics, antiemetics and antisecretory drugs, without the use of a venting nasogastric tube. Among the antisecretory drugs, octreotide has been shown to reduce nausea and vomiting in bowel-obstructed patients owing to a reduction of gastrointestinal secretions, thus allowing in most patients removal of the nasogastric tube and the associated distress. Preclinical and clinical studies that demonstrated the role of somatostatin and octreotide in bowel obstruction are reviewed.

KW - Bowel obstruction

KW - Clinical

KW - Experimental

KW - Octreotide

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0035056921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035056921&partnerID=8YFLogxK

M3 - Article

C2 - 11669548

AN - SCOPUS:0035056921

VL - 87

SP - 1

EP - 9

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -